AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney ...

On Friday, AstraZeneca ADR AZN reached a noteworthy performance benchmark, seeing its Relative Strength (RS) Rating jump into ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

NHS patients risk losing access to the world’s best medicines unless the UK spends more on developing new treatments, the ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.